AI Drug Discovery M&A: what is happening now?
In our AI in drug discovery market deck, you will find everything you need to understand the market
SUMMARY
AI Drug Discovery M&A: what is happening now? AI drug discovery M&A is heating up fast, but the center of gravity is not giant pharma takeovers; it is capability buying around data, workflow, clinical decision-making, and R&D infrastructure.
The market has clearly accelerated. We found 11 visible M&A or M&A-like deals over the last 24 months, with 9 in the most recent 12 months versus only 2 in the previous 12 months.
The acceleration is not just one noisy month. From January to May 2026 alone, there were 6 deals across AI-native biotech, Big Pharma, CRO/data, industrial software and general AI buyers.
The buyer base has changed more than the headline deal count suggests. This is no longer just AI drug discovery startups combining with each other; AstraZeneca, Siemens, IQVIA, Cohere and reportedly Anthropic are now part of the map.
The biggest disclosed deal is not a pure AI biotech acquisition. Siemens / Dotmatics at $5.1B shows that buyers may value the infrastructure around AI-enabled R&D more than the risky drug pipelines themselves.
For core AI drug discovery platform consolidation, Recursion / Exscientia remains the cleanest large reference point. At about $688M, it is meaningful, but it also shows that pure AI biotech platforms are being priced more selectively than scientific software infrastructure.
The most important pattern is that buyers are not acquiring “AI” in the abstract anymore. They are buying specific bottleneck-solvers: AI chemistry, biologics design, pathology AI, research intelligence, discovery services and AI-enabled asset selection.
Big Pharma’s behavior looks selective, not desperate. AstraZeneca / Modella AI suggests a “collaborate first, acquire later” pattern when the AI capability becomes close enough to a priority R&D workflow.
The market is also moving closer to clinical decisions. Pathos / DeuterOncology is especially interesting because AI was used to identify and evaluate a clinical oncology asset, not just to generate molecules upstream.
Valuation transparency remains weak. Many important deals are undisclosed, and the only clean revenue multiple we can calculate is IQVIA / Charles River selected assets at roughly 1.0x revenue upfront.
That modest multiple matters because it pushes back against the lazy conclusion that “AI drug discovery M&A is in a bubble.” Strategic appetite is clearly rising, but the disclosed evidence does not yet prove crazy acquisition multiples across the category.
All everything considered together, AI drug discovery M&A is still early, but it is no longer experimental. The market has moved from scattered AI-biotech consolidation into a broader strategic race to own the pieces that make AI useful inside real pharma R&D.
This market map, featured in our AI in drug discovery market deck, highlights top companies and startups in the AI in drug discovery market
What are the latest M&A deals in AI drug discovery?
When we look at all the M&A deals in AI drug discovery over the last 24 months, the market looks much more active now than it did a year ago, but the activity is still concentrated in capability deals rather than a long list of huge pharma takeovers.
| Date | Target | Acquirer | Value | Strategic rationale | Status and additional comment |
|---|---|---|---|---|---|
| May 2026 | Reliant AI | Cohere | Undisclosed | Cohere bought a biopharma research intelligence company to strengthen pharma-specific enterprise AI workflows. | Announced / acquired. A general AI company moved directly into pharma R&D workflows, not just generic enterprise AI. |
| May 2026 | DeuterOncology | Pathos AI | Undisclosed | Pathos bought a majority stake in a clinical oncology asset identified by its AI-enabled Foundry platform. | Announced. One of the most interesting deals because AI was used to source and evaluate the asset, not only to design molecules. |
| Apr 2026 | Coefficient Bio | Anthropic | Around $400M reported | Anthropic reportedly acquired a stealth AI-biotech team to build deeper healthcare and life-sciences capabilities. | Reported, not fully confirmed by company PR. Useful, but lower-confidence than official acquisition announcements. |
| Feb 2026 | Selected Charles River Discovery assets | IQVIA | $145M cash + up to $10M | IQVIA bought discovery services, curated scientific data, a small-molecule AI platform and five European sites. | Announced, expected close Q2 2026. The assets had $144M of 2025 revenue, so the deal implies roughly 1.0x revenue upfront. |
| Jan 2026 | Modella AI | AstraZeneca | Undisclosed | AstraZeneca bought an AI pathology and oncology R&D company after an earlier collaboration. | Announced / acquired. This looks like a “work together first, buy later” pattern in Big Pharma AI. |
| Jan 2026 | CombinAbleAI | insitro | Undisclosed | insitro bought AI-native biologics design capabilities and extended its TherML platform. | Announced, expected close late January 2026. This is a capability-completion deal: insitro had AI biology and added stronger biologics design. |
| Nov 2025 | Molecule.ai | Shuttle Pharmaceuticals | Up to $10M | Shuttle bought an AI platform using ML, LLMs and agentic AI for molecular property and drug-target modeling. | Closed. Small deal, but strategically clear: a public biotech bought AI capability instead of building it internally from zero. |
| Oct 2025 | Nanyang Biologics | RF Acquisition Corp II | $1.5B pre-transaction equity value | Nanyang used a SPAC transaction to pursue a public listing for its AI-driven natural-compound discovery platform. | Announced, expected close in Q1 or Q2 2026. This is M&A-like, but should be separated from classic strategic acquisitions. |
| Jul 2025 | Perpetual Medicines | TandemAI | Undisclosed | TandemAI and Perpetual merged AI/physics-based small-molecule discovery with computational peptide design. | Announced / merged. The combined company communicated 150+ partners and 10+ client programs expected to reach clinical trials within 12 months. |
| Jul 2025 | Dotmatics | Siemens | $5.1B enterprise value | Siemens bought life-sciences R&D software infrastructure to extend its AI-powered software stack into scientific data and drug development workflows. | Closed. Very large deal, but adjacent to pure AI drug discovery because Dotmatics is more R&D software infrastructure than an AI biotech platform. |
| Nov 2024 | Exscientia | Recursion Pharmaceuticals | About $688M all-stock | Recursion combined its biology and phenomics platform with Exscientia’s AI chemistry and molecule design engine. | Closed. This is the clearest platform-consolidation deal in the period: two public AI drug discovery companies merged into one larger AI-native drug developer. |
Is AI drug discovery M&A really active now?
Yes, AI drug discovery M&A is clearly active now, and the acceleration is too large to dismiss as noise.
When we look at all the M&A deals in AI drug discovery over the last 24 months, we count 11 transactions. Only 2 happened in the first 12-month period, while 9 happened in the most recent 12-month period. That is a 4.5x increase in deal count, which is a strong acceleration for a market that is still relatively young.
The timing is also compressed. From July 2025 to May 2026, there was a steady sequence of deals across several buyer types: TandemAI / Perpetual, Shuttle / Molecule.ai, insitro / CombinAbleAI, AstraZeneca / Modella AI, IQVIA / Charles River assets, Pathos / DeuterOncology and Cohere / Reliant AI. That rhythm shows the market did not just have one isolated headline transaction.
The recent deals are, actually, not all copies of each other. We see platform mergers, Big Pharma AI tuck-ins, CRO/discovery-service asset acquisitions, AI-sourced oncology asset acquisitions and enterprise AI companies buying pharma workflow capability.
So AI drug discovery M&A is not just “more deals.” It is a broader expansion of what buyers now consider strategically ownable.
If you want more recent data on this point, please see our latest AI in drug discovery market report.
As this chart shows, and as featured in our AI in drug discovery market deck, search interest in AI drug discovery has grown rapidly
Did AI drug discovery M&A accelerate recently, or are we just seeing one busy month?
AI drug discovery M&A has really accelerated recently, and it is not just one busy month creating a false impression.
The market had only one clear core AI drug discovery platform consolidation in the earlier part of the window: Recursion / Exscientia. The other large deal, Siemens / Dotmatics, was important but more adjacent because Dotmatics is life-sciences R&D software infrastructure. In the more recent period, the activity became both denser and more varied, with 9 deals in 12 months.
The last 6 months are especially telling. From January to May 2026 alone, we see insitro / CombinAbleAI, AstraZeneca / Modella AI, IQVIA / Charles River assets, Anthropic / Coefficient Bio, Pathos / DeuterOncology and Cohere / Reliant AI. That is 6 deals in roughly 5 months, versus 2 deals in the entire first 12 months of the 24-month window.
All things considered, the recent market looks less like random noise and more like a step-change. Buyers are no longer waiting for the perfect AI drug discovery company to appear. They are buying specific pieces of the stack when those pieces solve a clear internal problem.
Are big buyers now entering AI drug discovery M&A?
Yes, big buyers are now entering AI drug discovery M&A, and that is one of the clearest changes in the market.
The buyer list has become much more credible recently. AstraZeneca bought Modella AI to push AI into oncology R&D workflows. IQVIA agreed to buy Charles River discovery assets to expand earlier into discovery services. Siemens bought Dotmatics to move deeper into life-sciences software. Cohere acquired Reliant AI to strengthen biopharma and healthcare enterprise AI. Anthropic reportedly acquired Coefficient Bio to deepen life-sciences capabilities.
That buyer mix is important. These are not only AI drug discovery startups buying other AI drug discovery startups. The market now includes Big Pharma, CRO/data companies, industrial software companies and general AI labs. Each buyer is entering from a different angle, which makes the trend more robust.
We can conclude that AI drug discovery has crossed a strategic threshold. It is still early as an M&A market, but it is no longer only a startup-to-startup consolidation story. Larger companies now see AI drug discovery and pharma R&D AI as capabilities they may need to own, not just tools they can casually test.
If you want more recent data on this point, please see our latest AI in drug discovery market report.
This chart, featured in our AI in drug discovery market deck, shows annual venture capital investment in AI drug discovery startups
Are the biggest AI drug discovery deals happening inside pure AI biotech?
No, the biggest disclosed values are not coming from pure AI biotech takeovers.
The largest transaction in the 24-month window is Siemens / Dotmatics at $5.1B. That is a major life-sciences software deal, but Dotmatics is closer to scientific data infrastructure and R&D workflow software than to a pure AI biotech discovering its own medicines. The second largest visible number is Nanyang / RF Acquisition II at a $1.5B pre-transaction equity value, but that is a SPAC business combination, not a standard acquisition.
For pure platform-style AI drug discovery, Recursion / Exscientia at about $688M is the cleanest large deal. It brought together two public AI drug discovery companies, but the value is far below Dotmatics. That gap is useful: the market is placing large strategic value on the infrastructure around AI-enabled R&D, while pure AI biotech platform valuations remain more selective.
At the end of the day, the money is moving toward the parts of the market that look easiest to integrate into existing R&D systems: software, data, workflow, discovery services and specific capabilities. Pure AI drug discovery platforms still matter, but they are not the only place where strategic value is being recognized.
Is AI drug discovery M&A mostly about buying “AI platforms” now?
No, AI drug discovery M&A is now less about buying generic AI platforms and more about buying missing capabilities.
Recursion / Exscientia was the classic platform consolidation deal. Recursion brought large-scale biology, data generation and phenomics. Exscientia brought AI chemistry and molecule design. TandemAI / Perpetual also fits the platform logic, because it combined small-molecule AI/physics discovery with peptide design.
But the recent deals are more specific. insitro bought CombinAbleAI to extend from small molecules and oligonucleotides into antibodies and complex biologics. AstraZeneca bought Modella AI for oncology pathology, biomarkers and multimodal AI agents. IQVIA bought Charles River discovery assets that came with sites, curated data, services and a small-molecule AI platform. Cohere bought Reliant AI for pharma research intelligence rather than molecule generation.
So it looks like the market has moved from “AI platform sounds exciting” to “which exact workflow does this capability improve?” That is a more mature kind of buying behavior. Buyers are not acquiring AI as a label; they are acquiring something that can plug into discovery, design, pathology, evidence review, asset selection or early development.
If you want more recent data on this point, please see our latest AI in drug discovery market report.
This chart, featured in our AI in drug discovery market deck, shows how Shrödinger is positioned in AI drug discovery
Is Big Pharma buying AI drug discovery companies now?
Yes, Big Pharma is buying AI drug discovery capabilities now, but it is doing it selectively.
The clearest example is AstraZeneca / Modella AI. Modella works on biomedical AI for oncology, including multimodal foundation models and AI agents. AstraZeneca did not buy a broad AI discovery company with a vague promise. It bought a focused AI capability connected to oncology R&D, clinical workflows, pathology and biomarker insight.
The deal also followed an earlier collaboration. That suggests Big Pharma may not rush straight into acquisition. It may first test the AI company inside a real R&D workflow, then buy it if the technology becomes strategically embedded.
Compare AstraZeneca’s move with the absence of many other huge Big Pharma AI takeovers in the same window. Pharma appetite is real, but not indiscriminate. Big Pharma is more likely to buy AI companies when the target is close to a priority disease area, has workflow relevance and can be integrated into existing R&D processes.
Are AI drug discovery deals moving closer to clinical assets now?
Yes, AI drug discovery M&A is moving closer to clinical assets and development decisions.
The strongest example is Pathos AI / DeuterOncology. Pathos acquired a majority stake in a company developing DO-2, a clinical oncology asset. The key point is that Pathos said its AI-enabled Foundry platform identified and evaluated the opportunity. That turns AI from a molecule-design tool into a business development and asset-selection engine.
AstraZeneca / Modella AI also points toward the clinical side. Modella is not just about inventing molecules at the earliest discovery stage but, actually, about oncology R&D, pathology, biomarkers and clinical development workflows. IQVIA / Charles River assets add another useful clue because those assets had supported 100+ molecules entering clinical trials and several approved drugs.
The recent market is pulling AI drug discovery closer to points where decisions become expensive and consequential. This is probably where strategic buyers care most: not just “can AI generate a molecule?” but “can AI help us pick better assets, read better evidence, design better trials or reduce the risk of bad development decisions?”
If you want more recent data on this point, please see our latest AI in drug discovery market report.
This chart, featured in our AI in drug discovery market deck, shows annual funding in AI drug discovery startups
Are AI drug discovery buyers paying crazy multiples now?
No, we do not have evidence that AI drug discovery buyers are paying crazy multiples now.
Most transaction values are undisclosed. AstraZeneca / Modella AI, insitro / CombinAbleAI, TandemAI / Perpetual, Pathos / DeuterOncology and Cohere / Reliant AI did not disclose deal value. Even where value is visible, we often lack the revenue base, which makes multiple calculation weak.
The cleanest multiple is IQVIA / Charles River selected discovery assets. IQVIA agreed to pay $145M upfront plus up to $10M for assets that generated $144M of 2025 revenue. That implies roughly 1.0x revenue upfront and about 1.08x revenue including contingent payments. For an AI-related discovery asset package, that is not a “software-like” multiple. It looks more like a services and infrastructure acquisition with useful AI/data capabilities attached.
The Siemens / Dotmatics deal likely carries a much higher software valuation logic, but it sits in scientific software infrastructure rather than pure AI drug discovery. So the sharper conclusion is not “valuations are high.” It is that strategic appetite is rising, while the available M&A data does not prove a broad valuation bubble in AI drug discovery acquisitions.
Are AI companies now competing with pharma buyers in AI drug discovery M&A?
Yes, AI companies are now entering the same pharma R&D territory that used to belong mostly to biotech, pharma and CRO buyers.
Cohere / Reliant AI is the cleanest confirmed example. Cohere is a general enterprise AI company, and Reliant AI brings proprietary biomedical datasets, pharma research workflows and domain-optimized technology. That is a direct move into biopharma and healthcare vertical AI.
Anthropic / Coefficient Bio is a second example, although the deal should be treated more carefully because it was reported rather than fully confirmed through the same type of company announcement. Even so, the reported logic fits the same pattern: a leading AI company wants life-sciences talent and domain-specific capability.
The interpretation is important. General AI companies do not need to buy AI drug discovery companies because they lack models. They buy because pharma R&D is full of specialized data, regulatory context, scientific language and evidence standards. In practice, the hard part is often making AI useful inside real pharma workflows. That is why biopharma workflow companies can become M&A targets for general AI labs.
This chart, featured in our AI in drug discovery market deck, compares the main business model options for AI drug discovery biotech companies
Is AI drug discovery M&A becoming more about infrastructure than biotech?
Yes, a lot of AI drug discovery M&A is shifting toward infrastructure, workflow and data layers.
Siemens / Dotmatics is the clearest infrastructure example. Siemens paid $5.1B for scientific software that connects life-sciences R&D data, applications and decision-making. IQVIA / Charles River assets is another infrastructure-style deal, because IQVIA is buying sites, services, curated data and a small-molecule AI platform that can extend its discovery offering. Cohere / Reliant AI adds the research-intelligence layer, where the asset is not a molecule but a better way for pharma teams to process scientific and regulatory information.
That does not mean molecule-generation platforms are irrelevant. Recursion / Exscientia and TandemAI / Perpetual show that platform consolidation still happens. But the biggest disclosed value and several recent strategic moves sit around the systems that make AI usable in pharma: data, workflow, lab services, evidence extraction and software integration.
All everything considered together, the market may be easier to monetize first through infrastructure than through pure AI biotech pipelines. Infrastructure can sell into many R&D organizations, while an AI-discovered drug still has to survive the full clinical development risk curve.
If you want more recent data on this point, please see our latest AI in drug discovery market report.
Is AI drug discovery M&A still early, or already mature?
AI drug discovery M&A is still early, but it is no longer experimental.
It is still early because we found 11 visible M&A / M&A-like deals over 24 months, which is not a large number for a mature consolidation market. Also, value disclosure is weak, clean multiples are rare, and deal types vary a lot. A mature market would usually show more repeatable deal structures and more comparable valuation benchmarks.
But it is no longer experimental because the quality of buyers has changed. AstraZeneca, Siemens, IQVIA, Cohere, Recursion, insitro and Pathos AI are not casual participants. They are buying capabilities that can affect oncology R&D, discovery services, biologics design, scientific workflow, data infrastructure or asset selection.
So we can conclude that the market is in the transition zone. AI drug discovery M&A has moved past “interesting technology to watch,” but it has not yet become a fully standardized M&A category with predictable valuation rules.
This chart, featured in our AI in drug discovery market deck, shows revenue breakdown by customer segment in the AI in drug discovery market
So what is the latest update on AI drug discovery M&A?
When we look at all the M&A deals in AI drug discovery over the last 24 months, the latest update is clear: AI drug discovery M&A is heating up now.
So, yes, AI drug discovery M&A is accelerating, but the consolidation is happening around specific bottlenecks, not around the vague idea of “AI for drugs.”
Buyers want capabilities that help them design better molecules, read better evidence, select better assets, connect better data and move R&D decisions closer to the clinic.
| Check | Current status |
|---|---|
| Latest AI drug discovery deals | We found 11 M&A / M&A-like deals over 24 months. The most recent wave includes Cohere / Reliant AI, Pathos / DeuterOncology, Anthropic / Coefficient Bio, IQVIA / Charles River assets, AstraZeneca / Modella AI and insitro / CombinAbleAI. |
| Deal activity now | AI drug discovery M&A is clearly more active now. There were 9 deals in the last 12 months versus 2 in the previous 12 months, which means deal count increased by 4.5x. |
| Recent acceleration | The acceleration is not just one busy month. From January to May 2026 alone, we see 6 deals across pharma, AI, CRO/data and AI-native biotech buyers. |
| Biggest disclosed value | Siemens / Dotmatics at $5.1B is the biggest disclosed value, but it is adjacent infrastructure rather than a pure AI biotech platform deal. For core platform consolidation, Recursion / Exscientia at about $688M is the cleaner reference point. |
| Buyer types now | The buyer base has widened. We now see AI biotechs, Big Pharma, CRO/data companies, industrial software companies and general AI companies entering the AI drug discovery ecosystem. |
| Main strategic rationale | Buyers are acquiring missing capabilities, not generic AI branding. The recurring targets are AI chemistry, biologics design, pathology AI, research intelligence, discovery services and AI-enabled asset selection. |
| Big Pharma behavior | Big Pharma is selective. AstraZeneca / Modella AI suggests pharma buyers may acquire AI partners after collaboration, especially when the AI capability is close to a priority R&D workflow. |
| Clinical pull | AI drug discovery M&A is moving closer to clinical decisions. Pathos / DeuterOncology and AstraZeneca / Modella AI show AI being used around clinical assets, oncology biomarkers and development workflows. |
| Infrastructure pull | Infrastructure is becoming a major part of the market. Siemens / Dotmatics, IQVIA / Charles River assets and Cohere / Reliant AI all point toward software, data, services and workflow layers. |
| Valuation transparency | Valuation transparency remains weak. Several strategically important deals are undisclosed, and only IQVIA / Charles River assets gives enough revenue information to calculate a clean multiple. |
| Revenue multiples | The only clean multiple is modest: about 1.0x revenue upfront for IQVIA / Charles River selected assets. The current evidence does not support a broad claim that AI drug discovery M&A multiples are crazy. |
| Market maturity | AI drug discovery M&A is still early, but no longer experimental. Deal count is still modest, but the buyer quality and deal variety show that strategic ownership now matters. |
OUR METHODOLOGY
This analysis tests what is happening now in AI drug discovery M&A based on the evidence available today. We compare recent deal activity, acceleration, buyer quality, deal type, strategic rationale, valuation visibility, clinical pull, infrastructure pull and market maturity.
We treated the question of AI drug discovery M&A as too broad to answer from intuition alone. Instead of relying on a general feeling that the market is “hot,” we broke the analysis into several checks that could be tested against recent transactions.
For each check, we looked at recent evidence and kept the information that added something specific. Deal count helped us measure acceleration, buyer identity helped us separate small consolidation from strategic market entry, and deal rationale helped us understand what buyers were actually trying to own.
We separated core AI drug discovery platform deals from adjacent infrastructure, workflow, data and services deals. That distinction matters because the current wave is not only about buying AI biotech platforms; a large part of the value is moving toward the systems that make AI useful inside pharma R&D.
Those systems include scientific data, software, research intelligence, discovery services, pathology, biologics design and asset-selection workflows. That is why deals such as Siemens / Dotmatics, IQVIA / Charles River assets and Cohere / Reliant AI are treated as strategically important, even when they are not pure AI-biotech acquisitions.
For valuation, we only used clean multiples when both transaction value and revenue were visible. That is why the analysis gives more weight to the IQVIA / Charles River asset transaction than to undisclosed deals where a multiple would be speculative.
We treated reported but not fully company-confirmed transactions more carefully than official acquisition announcements. Anthropic / Coefficient Bio is therefore useful as a directional clue, but it carries lower confidence than deals announced directly by the companies involved.
This structured aggregation of recent evidence is what makes the final answer clearer. The conclusion is not based on one headline deal or a vague market narrative, but on repeated evidence across activity, timing, buyer behavior, strategic rationale and disclosed financials.
Key sources used for this analysis include: Siemens’ Dotmatics acquisition announcement, Siemens’ Dotmatics closing announcement, The Times on Recursion / Exscientia, The Economic Times on Anthropic / Coefficient Bio, Cohere, Reliant AI, AstraZeneca, Modella AI, IQVIA investor relations, Charles River investor relations, Dotmatics, Recursion investor relations, Exscientia investor relations archive, insitro, CombinAbleAI, Pathos AI, DeuterOncology, TandemAI, Perpetual Medicines, Shuttle Pharmaceuticals investor relations, and SEC filings context for Nanyang Biologics / RF Acquisition Corp II.
This chart, featured in our AI in drug discovery market deck, shows how AI drug discovery platform technology has evolved over time
Related blog posts
- How strong is fundraising in the AI in drug discovery market right now?
- Which companies have raised the most funding in AI for drug discovery?
- Which companies are the most valued in AI for drug discovery?
